{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:53:32Z","timestamp":1793840012050,"version":"4.6.1"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"European Union\u2019s Horizon 2020 research and innovation program under the Marie Sk\u0142odowska-Curie ITN initiative \u201cGLIOTRAIN\u201d","award":["766069 to L.W., K.W., A.T.B., D.L., G.B."],"award-info":[{"award-number":["766069 to L.W., K.W., A.T.B., D.L., G.B."]}]},{"name":"European Union\u2019s Horizon Europe research and innovation program under the Marie Sk\u0142odowska-Curie Doctoral Network GLIORESOLVE","award":["101073386 to K.S.G., A.T.B., F.D.S., G.B."],"award-info":[{"award-number":["101073386 to K.S.G., A.T.B., F.D.S., G.B."]}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["11L0822N, 11L0824N to M.V.; G026325N, G026225N, G0B3722N, S001221N, I005920N, G0I1118N to F.D.S.; S021124N to A.D.G."],"award-info":[{"award-number":["11L0822N, 11L0824N to M.V.; G026325N, G026225N, G0B3722N, S001221N, I005920N, G0I1118N to F.D.S.; S021124N to A.D.G."]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C14\/24\/122, C3\/23\/067 to A.D.G; CELSA\/20\/022 to F.D.S."],"award-info":[{"award-number":["C14\/24\/122, C3\/23\/067 to A.D.G; CELSA\/20\/022 to F.D.S."]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["VLIR-UOS [iBOF\/21\/048 to A.D.G.)"],"award-info":[{"award-number":["VLIR-UOS [iBOF\/21\/048 to A.D.G.)"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Olivia Hendrickx Research Foundation [to A.D.G.]"},{"name":"European Union Mission Cancer","award":["101136670 to A.D.G."],"award-info":[{"award-number":["101136670 to A.D.G."]}]},{"DOI":"10.13039\/501100005026","name":"Stichting Tegen Kanker","doi-asserted-by":"publisher","award":["2024-185 to A.D.G."],"award-info":[{"award-number":["2024-185 to A.D.G."]}],"id":[{"id":"10.13039\/501100005026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Health Research Board Ireland","award":["ILP-POR-2022-007 to A.T.B."],"award-info":[{"award-number":["ILP-POR-2022-007 to A.T.B."]}]},{"name":"Brain Tumour Ireland [to A.T.B.]"},{"name":"Beaumont Hospital Cancer Research and Development Trust [to A.T.B.]"},{"name":"Private Donation in support of RCSI PCM Group GBM Research Programme [to A.T.B.]"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immunotherapies have improved outcomes in many cancers but remain largely ineffective in glioblastoma (GBM). We investigated whether immunotherapy could be rationally tailored to GBM by functionally subtyping the tumor immune microenvironment (TIME) and associated vascular landscapes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Single-cell and single-nucleus RNA sequencing, multiplex immunohistochemistry, and flow cytometry were used to define TIME subtypes in human and murine GBMs. Therapeutic responses to anti-angiogenic and immunomodulatory therapies, including CD40 agonist, \u03b1PD-L1, and PI3K\u03b3\/\u03b4 inhibition, were assessed in orthotopic syngeneic GBM mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Three distinct functional TIME subtypes with unique vascular-immune landscapes were identified in human and murine GBM. TIME-low tumors were immune-low\/deserted with a leaky vasculature. TIME-med GBM exhibited intermediate immune-infiltration, prominent angiogenesis, and active immune responses. TIME-high tumors showed dense infiltration of immunosuppressive myeloid cells and dysfunctional T cells. Representative mouse models demonstrated subtype-specific sensitivities to anti-angiogenic immunomodulating therapies. TIME-low GBMs exhibited transient T-cell activation but relapsed due to myeloid-driven immunosuppression and mesenchymal transition. TIME-med tumors displayed the most favorable responses across anti-angiogenic immunomodulating therapies. TIME-high GBMs were largely resistant, although therapeutic efficacy improved with myeloid-targeted PI3K\u03b3 inhibition. In contrast, CD40 agonist therapy worsened survival by enhancing angiogenesis, amplifying immunosuppression, impairing T cell function, reducing NK-cell recruitment, and promoting tumor propagation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GBM comprises 3 functional TIME subtypes with divergent vascular-immune landscapes that require subtype-specific therapeutic strategies. TIME-med tumors are most amenable to immunotherapies. TIME-low tumors derive transient effects with anti-angiogenic immunomodulating therapies, and TIME-high are resistant or even experience worse outcome without targeted reversal of myeloid immunosuppression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag018","type":"journal-article","created":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:14:25Z","timestamp":1769516065000},"page":"1133-1149","source":"Crossref","is-referenced-by-count":5,"title":["Distinct tumor immune microenvironmental landscapes drive divergent immunotherapy responses in glioblastoma"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0965-4994","authenticated-orcid":false,"given":"Linqian","family":"Weng","sequence":"first","affiliation":[{"name":"Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish Skandha","family":"Gopalan","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Guyot","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Vanmechelen","sequence":"additional","affiliation":[{"name":"The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging & Pathology, KU Leuven , Leuven,","place":["Belgium"]},{"name":"KU Leuven Institute for Single Cell Omics (LISCO) , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Nazari","sequence":"additional","affiliation":[{"name":"The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging & Pathology, KU Leuven , Leuven,","place":["Belgium"]},{"name":"KU Leuven Institute for Single Cell Omics (LISCO) , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Duhamel","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clelia","family":"Donisi","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Pallar\u00e9s-Moratalla","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek D","family":"Garg","sequence":"additional","affiliation":[{"name":"Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"White","sequence":"additional","affiliation":[{"name":"Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland , Dublin,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette T","family":"Byrne","sequence":"additional","affiliation":[{"name":"Precision Cancer Medicine Group, Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland , Dublin,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3429-302X","authenticated-orcid":false,"given":"Diether","family":"Lambrechts","sequence":"additional","affiliation":[{"name":"Laboratory of Translational Genetics, VIB Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Laboratory of Translational Genetics, Department of Human Genetics and Leuven Cancer Institute, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"De Smet","sequence":"additional","affiliation":[{"name":"The Laboratory for Precision Cancer Medicine, Translational Cell and Tissue Research Unit, Department of Imaging & Pathology, KU Leuven , Leuven,","place":["Belgium"]},{"name":"KU Leuven Institute for Single Cell Omics (LISCO) , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3545-5171","authenticated-orcid":false,"given":"Gabriele","family":"Bergers","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Microenvironment and Therapeutic Resistance, VIB-KU Leuven Center for Cancer Biology , Leuven,","place":["Belgium"]},{"name":"Department of Oncology, KU Leuven , Leuven,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"2026051916122493300_noag018-B1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"2026051916122493300_noag018-B2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/path.5080","article-title":"Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules","volume":"245","author":"He","year":"2018","journal-title":"J Pathol"},{"key":"2026051916122493300_noag018-B3","doi-asserted-by":"publisher","first-page":"aak9670","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026051916122493300_noag018-B4","doi-asserted-by":"publisher","first-page":"aak9679","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026051916122493300_noag018-B5","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"2026051916122493300_noag018-B6","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2026051916122493300_noag018-B7","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"2026051916122493300_noag018-B8","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat Med"},{"key":"2026051916122493300_noag018-B9","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026051916122493300_noag018-B10","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2026051916122493300_noag018-B11","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026051916122493300_noag018-B12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N Engl J Med"},{"key":"2026051916122493300_noag018-B13","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"2026051916122493300_noag018-B14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1158\/1078-0432.ccr-20-2500","article-title":"Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma","volume":"27","author":"Nayak","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"2026051916122493300_noag018-B15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.annonc.2022.11.008","article-title":"Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy","volume":"34","author":"White","year":"2023","journal-title":"Ann Oncol"},{"key":"2026051916122493300_noag018-B16","doi-asserted-by":"publisher","first-page":"7362","DOI":"10.1038\/s41467-024-50618-0","article-title":"Community assessment of methods to deconvolve cellular composition from bulk gene expression","volume":"15","author":"White","year":"2024","journal-title":"Nat Commun"},{"key":"2026051916122493300_noag018-B17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","article-title":"The technological landscape and applications of single-cell multi-omics","volume":"24","author":"Baysoy","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026051916122493300_noag018-B18","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41588-025-02167-5","article-title":"The multilayered transcriptional architecture of glioblastoma ecosystems","volume":"57","author":"Nomura","year":"2025","journal-title":"Nat Genet"},{"key":"2026051916122493300_noag018-B19","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/s41588-025-02168-4","article-title":"Deciphering the longitudinal trajectories of glioblastoma ecosystems by integrative single-cell genomics","volume":"57","author":"Spitzer","year":"2025","journal-title":"Nat Genet"},{"key":"2026051916122493300_noag018-B20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41593-020-00789-y","article-title":"Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization","volume":"24","author":"Pombo Antunes","year":"2021","journal-title":"Nat Neurosci"},{"key":"2026051916122493300_noag018-B21","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","article-title":"A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets","volume":"3","author":"Wang","year":"2022","journal-title":"Nat Cancer"},{"key":"2026051916122493300_noag018-B22","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2023.11.032","article-title":"Time-resolved single-cell transcriptomics defines immune trajectories in glioblastoma","volume":"187","author":"Kirschenbaum","year":"2024","journal-title":"Cell"},{"key":"2026051916122493300_noag018-B23","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ccell.2021.05.002","article-title":"Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma","volume":"39","author":"Hara","year":"2021","journal-title":"Cancer Cell"},{"key":"2026051916122493300_noag018-B24","doi-asserted-by":"publisher","first-page":"giaf076","DOI":"10.1093\/gigascience\/giaf076","article-title":"SeuratExtend: streamlining single-cell RNA-seq analysis through an integrated and intuitive framework","volume":"14","author":"Hua","year":"2025","journal-title":"Gigascience."},{"key":"2026051916122493300_noag018-B25","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1093\/neuonc\/noaf113","article-title":"Charting the single-cell and spatial landscape of IDH-wildtype glioblastoma with GBmap","volume":"27","author":"Ruiz-Moreno","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026051916122493300_noag018-B26","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","article-title":"Glioma progression is shaped by genetic evolution and microenvironment interactions","volume":"185","author":"Varn","year":"2022","journal-title":"Cell. Published"},{"key":"2026051916122493300_noag018-B27","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/neuonc\/noad021","article-title":"GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data","volume":"25","author":"Ajaib","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026051916122493300_noag018-B28","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"2026051916122493300_noag018-B29","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-023-02371-y","article-title":"Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance","volume":"29","author":"Chu","year":"2023","journal-title":"Nat Med"},{"key":"2026051916122493300_noag018-B30","doi-asserted-by":"publisher","first-page":"eadd1016","DOI":"10.1126\/scitranslmed.add1016","article-title":"Multiomics and spatial mapping characterizes human CD8+ T cell states in cancer","volume":"15","author":"Naulaerts","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026051916122493300_noag018-B31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.cell.2018.05.061","article-title":"Recovering gene interactions from single-cell data using data diffusion","volume":"174","author":"van Dijk","year":"2018","journal-title":"Cell"},{"key":"2026051916122493300_noag018-B32","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41577-025-01161-6","article-title":"The diversity of CD8+ T cell dysfunction in cancer and viral infection","volume":"25","author":"Galluzzi","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"2026051916122493300_noag018-B33","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature. Published"},{"key":"2026051916122493300_noag018-B34","doi-asserted-by":"publisher","first-page":"5336","DOI":"10.1016\/j.cell.2024.07.030","article-title":"Macrophage-mediated myelin recycling fuels brain cancer malignancy","volume":"187","author":"Kloosterman","year":"2024","journal-title":"Cell. Published"},{"key":"2026051916122493300_noag018-B35","doi-asserted-by":"publisher","first-page":"e150861","DOI":"10.1172\/jci.insight.150861","article-title":"Key molecular alterations in endothelial cells in human glioblastoma uncovered through single-cell RNA sequencing","volume":"6","author":"Xie","year":"2021","journal-title":"JCI Insight"},{"key":"2026051916122493300_noag018-B36","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41586-024-07698-1","article-title":"Tumour vasculature at single-cell resolution","volume":"632","author":"Pan","year":"2024","journal-title":"Nature. Published"},{"key":"2026051916122493300_noag018-B37","doi-asserted-by":"publisher","first-page":"e27706","DOI":"10.7554\/eLife.27706","article-title":"Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis","volume":"7","author":"Vervoort","year":"2018","journal-title":"Elife"},{"key":"2026051916122493300_noag018-B38","doi-asserted-by":"publisher","first-page":"6834","DOI":"10.1038\/onc.2008.287","article-title":"Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-beta signaling","volume":"27","author":"Pen","year":"2008","journal-title":"Oncogene"},{"key":"2026051916122493300_noag018-B39","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","article-title":"Understanding tumour endothelial cell heterogeneity and function from single-cell omics","volume":"23","author":"Zeng","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"2026051916122493300_noag018-B40","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1038\/s41467-020-17704-5","article-title":"Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types","volume":"11","author":"Khalsa","year":"2020","journal-title":"Nat Commun"},{"key":"2026051916122493300_noag018-B41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1349-7006.2006.00208.x","article-title":"Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy","volume":"97","author":"Szatm\u00e1ri","year":"2006","journal-title":"Cancer Sci"},{"key":"2026051916122493300_noag018-B42","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s42003-025-08092-x","article-title":"Single-nucleus RNA sequencing reveals a preclinical model for the most common subtype of glioblastoma","volume":"8","author":"Garc\u00eda-Vicente","year":"2025","journal-title":"Commun Biol"},{"key":"2026051916122493300_noag018-B43","doi-asserted-by":"publisher","first-page":"e1501137","DOI":"10.1080\/2162402X.2018.1501137","article-title":"Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models","volume":"7","author":"Genoud","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026051916122493300_noag018-B44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1172\/JCI58215","article-title":"Heparan sulfate sulfatase SULF2 regulates PDGFR\u03b1 signaling and growth in human and mouse malignant glioma","volume":"122","author":"Phillips","year":"2012","journal-title":"J Clin Invest"},{"key":"2026051916122493300_noag018-B45","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ccr.2012.05.037","article-title":"VEGF inhibits tumor cell invasion and mesenchymal transition through a MET\/VEGFR2 complex","volume":"22","author":"Lu","year":"2012","journal-title":"Cancer Cell"},{"key":"2026051916122493300_noag018-B46","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1126\/science.1226929","article-title":"Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice","volume":"338","author":"Friedmann-Morvinski","year":"2012","journal-title":"Science"},{"key":"2026051916122493300_noag018-B47","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nm.1863","article-title":"Development of a novel mouse glioma model using lentiviral vectors","volume":"15","author":"Marumoto","year":"2009","journal-title":"Nat Med"},{"key":"2026051916122493300_noag018-B48","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1158\/2159-8290.CD-19-1355","article-title":"Myeloid-Derived suppressor cell subsets drive glioblastoma growth in a Sex-Specific manner","volume":"10","author":"Bayik","year":"2020","journal-title":"Cancer Discov"},{"key":"2026051916122493300_noag018-B49","doi-asserted-by":"publisher","first-page":"11003","DOI":"10.1038\/s41598-020-67411-w","article-title":"GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models","volume":"10","author":"Sanchez","year":"2020","journal-title":"Sci Rep"},{"key":"2026051916122493300_noag018-B50","doi-asserted-by":"publisher","first-page":"e2111003119","DOI":"10.1073\/pnas.2111003119","article-title":"STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models","volume":"119","author":"Berger","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026051916122493300_noag018-B51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.ccell.2022.12.007","article-title":"MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors","volume":"41","author":"Kilian","year":"2023","journal-title":"Cancer Cell."},{"key":"2026051916122493300_noag018-B52","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1093\/brain\/awaf129","article-title":"Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma","volume":"148","author":"Soni","year":"2025","journal-title":"Brain"},{"key":"2026051916122493300_noag018-B53","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1007\/s13311-015-0407-1","article-title":"Improved treatment efficacy of antiangiogenic therapy when combined with picornavirus vaccination in the GL261 glioma model","volume":"13","author":"Renner","year":"2016","journal-title":"Neurotherapeutics"},{"key":"2026051916122493300_noag018-B54","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","volume":"4","author":"Reardon","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"2026051916122493300_noag018-B55","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.cell.2021.01.022","article-title":"Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis","volume":"184","author":"Mathewson","year":"2021","journal-title":"Cell"},{"key":"2026051916122493300_noag018-B56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","article-title":"Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq","volume":"352","author":"Tirosh","year":"2016","journal-title":"Science"},{"key":"2026051916122493300_noag018-B57","doi-asserted-by":"publisher","first-page":"4827","DOI":"10.1038\/s41467-022-32552-1","article-title":"A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues","volume":"13","author":"Saul","year":"2022","journal-title":"Nat Commun"},{"key":"2026051916122493300_noag018-B58","doi-asserted-by":"publisher","first-page":"6938","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat Commun"},{"key":"2026051916122493300_noag018-B59","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/neuonc\/noae085","article-title":"Immunotherapy drives mesenchymal tumour cell state shift and TME immune response in glioblastoma patients","volume":"26","author":"Hendriksen","year":"2024","journal-title":"Neuro Oncol"},{"key":"2026051916122493300_noag018-B60","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"2026051916122493300_noag018-B61","doi-asserted-by":"publisher","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"McFaline-Figueroa","year":"2024","journal-title":"Nat Commun"},{"key":"2026051916122493300_noag018-B62","doi-asserted-by":"publisher","first-page":"eabn5649","DOI":"10.1126\/scitranslmed.abn5649","article-title":"Immunotoxin-\u03b1CD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models","volume":"15","author":"Parker","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026051916122493300_noag018-B63","doi-asserted-by":"publisher","first-page":"eabd1346","DOI":"10.1126\/scitranslmed.abd1346","article-title":"Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer","volume":"13","author":"Garris","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026051916122493300_noag018-B64","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s43018-022-00329-6","article-title":"Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targeting","volume":"3","author":"Salomon","year":"2022","journal-title":"Nat Cancer"},{"key":"2026051916122493300_noag018-B65","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1038\/s41467-021-24347-7","article-title":"Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma","volume":"12","author":"van Hooren","year":"2021","journal-title":"Nat Commun"},{"key":"2026051916122493300_noag018-B66","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/neuonc\/nov090","article-title":"CD40\/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models","volume":"17","author":"Chonan","year":"2015","journal-title":"Neuro Oncol"},{"key":"2026051916122493300_noag018-B67","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1038\/s41591-024-02978-9","article-title":"A spatial architecture-embedding HLA signature to predict clinical response to immunotherapy in renal cell carcinoma","volume":"30","author":"Kinget","year":"2024","journal-title":"Nat Med"},{"key":"2026051916122493300_noag018-B68","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","article-title":"SCENIC: single-cell regulatory network inference and clustering","volume":"14","author":"Aibar","year":"2017","journal-title":"Nat Methods"},{"key":"2026051916122493300_noag018-B69","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nm.2158","article-title":"A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications","volume":"16","author":"Sheng","year":"2010","journal-title":"Nat Med"},{"key":"2026051916122493300_noag018-B70","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.neo.2018.08.007","article-title":"Nuclear factor I represses the notch effector HEY1 in glioblastoma","volume":"20","author":"Brun","year":"2018","journal-title":"Neoplasia"},{"key":"2026051916122493300_noag018-B71","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"2026051916122493300_noag018-B72","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"key":"2026051916122493300_noag018-B73","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.celrep.2015.03.055","article-title":"Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy","volume":"11","author":"Rivera","year":"2015","journal-title":"Cell Rep"},{"key":"2026051916122493300_noag018-B74","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"2026051916122493300_noag018-B75","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"2026051916122493300_noag018-B76","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat Med"},{"key":"2026051916122493300_noag018-B77","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1215\/15228517-2009-004","article-title":"DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma","volume":"11","author":"Maes","year":"2009","journal-title":"Neuro Oncol"},{"key":"2026051916122493300_noag018-B78","doi-asserted-by":"crossref","first-page":"328ra27","DOI":"10.1126\/scitranslmed.aae0105","article-title":"Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell\u2013driven rejection of high-grade glioma","volume":"8","author":"Garg","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026051916122493300_noag018-B79","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13046-022-02251-2","article-title":"Immunotherapy for glioblastoma: the promise of combination strategies","volume":"41","author":"Bausart","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"2026051916122493300_noag018-B80","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"2026051916122493300_noag018-B81","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","article-title":"Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody","volume":"25","author":"Vonderheide","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026051916122493300_noag018-B82","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1093\/annonc\/mdv387","article-title":"A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma","volume":"26","author":"Nowak","year":"2015","journal-title":"Ann Oncol"},{"key":"2026051916122493300_noag018-B83","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1158\/2326-6066.CIR-24-0797","article-title":"Sustained macrophage reprogramming is required for CD8+ T cell-dependent long-term tumor eradication","volume":"13","author":"Jardim","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"2026051916122493300_noag018-B84","doi-asserted-by":"publisher","first-page":"102204","DOI":"10.1016\/j.xcrm.2025.102204","article-title":"Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas","volume":"6","author":"Labiano","year":"2025","journal-title":"Cell Rep Med"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag018\/66678241\/noag018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1133\/66678241\/noag018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1133\/66678241\/noag018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:12:32Z","timestamp":1779221552000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/5\/1133\/8450324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":84,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,31]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag018","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,31]]}}}